ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

Similar documents
**CRITERIA UNDER CMS REVIEW**

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

ALLERGIC CONJUNCTIVITIS AGENTS

ATYPICAL ANTIPSYCHOTICS

2017 Step Therapy Criteria

JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

FirstCarolinaCare Insurance Company. Step Therapy Requirements

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

ANTICONVULSANT STEP THERAPY

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

Step Therapy Requirements. Effective: 1/1/2019

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

Step Therapy Requirements. Effective: 11/01/2018

ANTICONVULSANTS. Details

Step Therapy Medications

ANTIDIABETIC AGENTS - MISCELLANEOUS

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Step Therapy Requirements

ANTIDIABETIC AGENTS - MISCELLANEOUS

Step Therapy Requirements. Effective: 05/01/2018

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

ANTICONVULSANTS. Details

ANTIDIABETIC AGENTS - MISCELLANEOUS

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO), Stride SM Value Rx Plus (HMO) and Stride SM Gain Rx (HMO)

2018 PDP Premier Step Therapy Document September 2018 Y0114_18_33144_I_009

ADHD STIMULANTS-S(SHC)

CARE N CARE HEALTH PLAN

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.

STEP THERAPY CRITERIA

Commissioner for the Department for Medicaid Services Selections for Preferred Products

Y0133_StepTherapyCriteria _C 10/18/18 Y0133_StepTherapyCriteria _C es 10/18/18

SmithRx Standard Formulary Step Therapy List

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

ANTICONVULSANT THERAPY

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

STEP THERAPY ALGORITHMS PUP Select Formulary

CARE N CARE HEALTH PLAN

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

Step Therapy Group. Atypical Antipsychotic Agents

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO) and Stride SM Value Rx Plus (HMO) Step Therapy Requirements

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

CARE N CARE HEALTH PLAN

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Step Therapy Criteria

Cigna Drug and Biologic Coverage Policy

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria

SelectHealth Advantage 2018 Step Therapy Criteria Previous trial on at least ONE: Generic topical acne treatment

ADHD STIMULANTS - SCORE

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

BRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX

Kansas Health Advantage (HMO SNP) 2018 Formulary Quantity Limit Criteria

Step Therapy Requirements

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Optima Tier Gold Formulary Date Effective: November 1, 2018.

Step Therapy Criteria

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Health Choice Generations 1 Tier Gold Effective Date: 11/01/2018.

Step Therapy Requirements. Effective: 03/01/2015

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

SelectHealth Advantage 2018 Step Therapy Criteria. Previous trial on at least ONE: Generic topical acne treatment. Previous trial on: alendronate

ACYCLOVIR OINT (CCHP2017)

Step Therapy Medications

ADHD STIMULANTS - SCORE

APREPITANT ARMODAFINIL BELSOMRA BUPAP BUPRENORPHINE HCL BUTALBITAL-ACETAMINOPHEN BUTALBITAL-APAP-CAFF-COD BUTALBITAL-APAP-CAFFEINE

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Farm Bureau Health Plans Date Effective: November 1, 2018.

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

2018 Step Therapy Criteria

Drug List Oregon (OR) This formulary was updated on April 22, 2018.

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir

Tribute 2018 Formulary 2018 Quantity Limit Criteria

Transcription:

Step Therapy Date Effective: April 1, 2019 ANTICONVULSANTS APTIOM TABLET 200 MG ORAL APTIOM TABLET 400 MG ORAL APTIOM TABLET 600 MG ORAL APTIOM TABLET 800 MG ORAL BANZEL SUSPENSION 40 MG/ML ORAL BANZEL TABLET 200 MG ORAL BANZEL TABLET 400 MG ORAL BRIVIACT SOLUTION 10 MG/ML ORAL BRIVIACT TABLET 10 MG ORAL BRIVIACT TABLET 100 MG ORAL BRIVIACT TABLET 25 MG ORAL BRIVIACT TABLET 50 MG ORAL BRIVIACT TABLET 75 MG ORAL CELONTIN CAPSULE 300 MG ORAL FYCOMPA SUSPENSION 0.5 MG/ML ORAL FYCOMPA TABLET 10 MG ORAL FYCOMPA TABLET 12 MG ORAL FYCOMPA TABLET 2 MG ORAL FYCOMPA TABLET 4 MG ORAL FYCOMPA TABLET 6 MG ORAL FYCOMPA TABLET 8 MG ORAL PEGANONE TABLET 250 MG ORAL SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL SYMPAZAN FILM 10 MG ORAL SYMPAZAN FILM 20 MG ORAL SYMPAZAN FILM 5 MG ORAL VIMPAT SOLUTION 10 MG/ML ORAL VIMPAT TABLET 100 MG ORAL VIMPAT TABLET 150 MG ORAL VIMPAT TABLET 200 MG ORAL VIMPAT TABLET 50 MG ORAL Claim will pay automatically for Brand Anticonvulsants if enrollee has a paid claim for at least a 1 days supply of a Generic Anticonvulsant or Tegretol XR or Epidiolex in the past 365 days. Otherwise, Brand Anticonvulsants require a step therapy exception request indicating: (1) history of inadequate treatment response with Generic Anticonvulsants or Tegetrol XR or Epidiolex, OR (2) history of adverse event with Generic Anticonvulsants or Tegretol XR or Epidiolex, OR (3)Generic Anticonvulsants or Tegretol XR or Epidiolex is contraindicated. Formulary ID 19510 and 19512 1

ANTIDEPRESSANTS amoxapine tablet 100 mg oral amoxapine tablet 150 mg oral amoxapine tablet 25 mg oral amoxapine tablet 50 mg oral citalopram hydrobromide solution 10 mg/5ml oral citalopram hydrobromide tablet 10 mg oral citalopram hydrobromide tablet 20 mg oral citalopram hydrobromide tablet 40 mg oral EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL MARPLAN TABLET 10 MG ORAL VIIBRYD STARTER PACK KIT 10 & 20 MG ORAL VIIBRYD TABLET 10 MG ORAL VIIBRYD TABLET 20 MG ORAL VIIBRYD TABLET 40 MG ORAL Claim will pay automatically for Amoxapine, Citalopram, Emsam, Marplan or Vibryd if enrollee has a paid claim for at least a 1 days supply of a generic formulary antidepressant in the past 365 days. Otherwise, Amoxapine, Citalopram, Emsam, Marplan or Vibryd require a step therapy exception request indicating: (1) history of inadequate treatment response with Step 1 Antidepressant, OR (2) history of adverse event with Step 1 Antidepressant, OR (3)Step 1 Antidepressant is contraindicated. 2

Step Therapy Date Effective: April 1, 2019 ATYPICALS clozapine tablet 100 mg oral clozapine tablet 200 mg oral clozapine tablet dispersible 100 mg oral clozapine tablet dispersible 12.5 mg oral clozapine tablet dispersible 150 mg oral clozapine tablet dispersible 200 mg oral clozapine tablet dispersible 25 mg oral FANAPT TABLET 1 MG ORAL FANAPT TABLET 10 MG ORAL FANAPT TABLET 12 MG ORAL FANAPT TABLET 2 MG ORAL FANAPT TABLET 4 MG ORAL FANAPT TABLET 6 MG ORAL FANAPT TABLET 8 MG ORAL FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL FAZACLO TABLET DISPERSIBLE 100 MG ORAL FAZACLO TABLET DISPERSIBLE 12.5 MG ORAL FAZACLO TABLET DISPERSIBLE 150 MG ORAL FAZACLO TABLET DISPERSIBLE 200 MG ORAL FAZACLO TABLET DISPERSIBLE 25 MG ORAL GEODON SOLUTION RECONSTITUTED 20 MG INTRAMUSCULAR SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL SAPHRIS TABLET SUBLINGUAL 2.5 MG SUBLINGUAL SAPHRIS TABLET SUBLINGUAL 5 MG SUBLINGUAL VRAYLAR CAPSULE 1.5 MG ORAL VRAYLAR CAPSULE 3 MG ORAL VRAYLAR CAPSULE 4.5 MG ORAL VRAYLAR CAPSULE 6 MG ORAL VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL ZYPREXA RELPREVV SUSPENSION RECONSTITUTED 210 MG INTRAMUSCULAR Claim will pay automatically for Clozapine (Tabs or ODT), Fanapt, Fazaclo, Geodon inj, Saphris, Vraylar, or ZYyprexa Relprevv if enrollee has a paid claim for at least a 1 days supply of 2 generic formulary atypicals in the past 365 days. Otherwise, Non-Preferred Antipsychotics require a step therapy exception request indicating any ONE of the following (1) Diagnosis that is not covered by generic formulary products (i.e. Acute treatment of agitation for Geodon injection), OR (2) History of inadequate treatment response with generic formulary products, OR (3) History of adverse event with generic formulary products, OR (4) Generic formulary products are contraindicated Formulary ID 19510 and 19512 3

CELECOXIB celecoxib capsule 100 mg oral celecoxib capsule 200 mg oral celecoxib capsule 400 mg oral celecoxib capsule 50 mg oral Claim will pay automatically for Celecoxib if enrollee has a paid claim for at least a 1 days supply of a generic formulary NSAID in the member's overall utilization history (lifetime). Otherwise, Celecoxib requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic formulary NSAID, OR (2) history of adverse event with any generic formulary NSAID, OR (3) any generic formulary NSAID is contraindicated. 4

Step Therapy Date Effective: April 1, 2019 CNS STIMULANTS atomoxetine hcl capsule 10 mg oral atomoxetine hcl capsule 100 mg oral atomoxetine hcl capsule 18 mg oral atomoxetine hcl capsule 25 mg oral atomoxetine hcl capsule 40 mg oral atomoxetine hcl capsule 60 mg oral atomoxetine hcl capsule 80 mg oral Claim will pay automatically for ATOMOXETINE if enrollee has paid claims history for any one of the following formulary CNS stimulants: amphetamine salts, dexmethylphenidate, dextroamphetamine, methylphenidate OR guanfacine ER. Otherwise, ATOMOXETINE requires a step therapy exception request indicating: (1) history of inadequate treatment response with amphetamine salts, dexmethylphenidate, dextroamphetaminemethylphenidate, OR guanfacine ER OR (2) history of adverse event with amphetamine salts, dexmethylphenidate, dextroamphetamine, methylphenidate, OR guanfacine ER OR (3)amphetamine salts, dexmethylphenidate, dextroamphetamine, methylphenidate OR guanfacine ER is contraindicated. Formulary ID 19510 and 19512 5

ELIDEL ELIDEL CREAM 1 % EXTERNAL pimecrolimus cream 1 % external Claim will pay automatically for Elidel (pimecrolimus) if enrollee has paid claims history for at least 2 different formulary topical steroids. 6

Step Therapy Date Effective: April 1, 2019 PPI DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL Claim will pay automatically for Dexilant if the enrollee has paid claims history of any 1 days supply of any single Step 1 agent in the member's overall utilization history (lifetime). Step 1 Drugs are: esomeprazole, omeprazole, pantoprazole. Otherwise, Dexilant requires a step therapy exception request indicating: (1) history of inadequate treatment response with Step 1 Drugs OR (2) history of adverse event with Step 1 Drugs OR (3) Step 1 Drugs are contraindicated Formulary ID 19510 and 19512 7

PROLIA PROLIA SOLUTION 60 MG/ML SUBCUTANEOUS Claim will pay automatically for Prolia if enrollee has a paid claim for at least a 1 days supply of Alendronate, Ibandronate or Risedroante in the past 365 days. Otherwise, Prolia requires a step therapy exception request indicating: (1) history of inadequate treatment response with Alendronate, Ibandronate or Risedroante, OR (2) history of adverse event with Alendronate, Ibandronate or Risedroante, OR (3) Alendronate, Ibandronate or Risedroante is contraindicated. 8

Step Therapy Date Effective: April 1, 2019 RANEXA RANEXA TABLET EXTENDED RELEASE 12 HOUR 1000 MG ORAL RANEXA TABLET EXTENDED RELEASE 12 HOUR 500 MG ORAL Claim will pay automatically for Ranexa if enrollee has a paid claim for at least a 1 day supply of Amlodipine, Atenolol, Diltiazem, Isosorbide dinitrate, Isosorbide mononitrate, Metoprolol ER, Minitran patch, Nadolol, Nicardipine, Nitroglycerin, Propranolol in the past 365 days. otherwise Ranexa requires a step therapy exception request indication any one of the following: (1) History of inadequate treatment response with step 1 agents or (2) History of adverse event with a step 1 agent or (3) Step 1 agents are contraindicated. Formulary ID 19510 and 19512 9

RYTARY RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL Claim will pay automatically for Rytary if enrollee has a paid claim for at least a 1 days supply of generic Carbidopa/Levodopa in the member's overall utilization history (lifetime). Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with Carbidopa/Levodopa, OR (2) history of adverse event with Carbidopa/Levodopa, OR (3) Carbidopa/Levodopa is contraindicated. 10

Step Therapy Date Effective: April 1, 2019 TRELEGY TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/INH INHALATION Claim will pay automatically for Trelegy if enrollee has a paid claim for at least 1 day supply of Advair Diskus, Advair HFA, Anoro, Breo Ellipta, Combivent, Daliresp, Fluticasone-Salmeterol Aerosol, Serevent, Spiriva, Stiolto in the past 365 days. Otherwise, Trelegy will require a step therapy exception request indicating: (1) history of inadequate treatment response with STEP 1 Agent, OR (2) history of adverse event with STEP 1 Agent, OR (3) STEP 1 Agent is contraindicated. Formulary ID 19510 and 19512 11

ULORIC ULORIC TABLET 40 MG ORAL ULORIC TABLET 80 MG ORAL Claim will pay automatically for Uloric if enrollee has a paid claim for at least a 1 days supply of Allopurinol in the past 365 days. Otherwise, Uloric requires a step therapy exception request indicating: (1) history of inadequate treatment response with Allopurinol, OR (2) history of adverse event with Allopurinol, OR (3) Allopurinol is contraindicated. 12

Step Therapy Date Effective: April 1, 2019 Index of Drugs/Alphabetical Listing A amoxapine tablet 100 mg oral... 2 amoxapine tablet 150 mg oral... 2 amoxapine tablet 25 mg oral... 2 amoxapine tablet 50 mg oral... 2 APTIOM TABLET 200 MG ORAL... 1 APTIOM TABLET 400 MG ORAL... 1 APTIOM TABLET 600 MG ORAL... 1 APTIOM TABLET 800 MG ORAL... 1 atomoxetine hcl capsule 10 mg oral... 5 atomoxetine hcl capsule 100 mg oral... 5 atomoxetine hcl capsule 18 mg oral... 5 atomoxetine hcl capsule 25 mg oral... 5 atomoxetine hcl capsule 40 mg oral... 5 atomoxetine hcl capsule 60 mg oral... 5 atomoxetine hcl capsule 80 mg oral... 5 B BANZEL SUSPENSION 40 MG/ML ORAL... 1 BANZEL TABLET 200 MG ORAL... 1 BANZEL TABLET 400 MG ORAL... 1 BRIVIACT SOLUTION 10 MG/ML ORAL... 1 BRIVIACT TABLET 10 MG ORAL... 1 BRIVIACT TABLET 100 MG ORAL... 1 BRIVIACT TABLET 25 MG ORAL... 1 BRIVIACT TABLET 50 MG ORAL... 1 BRIVIACT TABLET 75 MG ORAL... 1 C celecoxib capsule 100 mg oral... 4 celecoxib capsule 200 mg oral... 4 celecoxib capsule 400 mg oral... 4 celecoxib capsule 50 mg oral... 4 CELONTIN CAPSULE 300 MG ORAL... 1 citalopram hydrobromide solution 10 mg/5ml oral... 2 citalopram hydrobromide tablet 10 mg oral 2 citalopram hydrobromide tablet 20 mg oral 2 citalopram hydrobromide tablet 40 mg oral 2 clozapine tablet 100 mg oral... 3 clozapine tablet 200 mg oral... 3 clozapine tablet dispersible 100 mg oral... 3 clozapine tablet dispersible 12.5 mg oral... 3 clozapine tablet dispersible 150 mg oral... 3 clozapine tablet dispersible 200 mg oral... 3 clozapine tablet dispersible 25 mg oral... 3 D DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL... 7 DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL... 7 E ELIDEL CREAM 1 % EXTERNAL... 6 EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL... 2 EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL... 2 EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL... 2 F FANAPT TABLET 1 MG ORAL... 3 FANAPT TABLET 10 MG ORAL... 3 FANAPT TABLET 12 MG ORAL... 3 FANAPT TABLET 2 MG ORAL... 3 FANAPT TABLET 4 MG ORAL... 3 FANAPT TABLET 6 MG ORAL... 3 FANAPT TABLET 8 MG ORAL... 3 FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL... 3 FAZACLO TABLET DISPERSIBLE 100 MG ORAL... 3 FAZACLO TABLET DISPERSIBLE 12.5 MG ORAL... 3 FAZACLO TABLET DISPERSIBLE 150 MG ORAL... 3 FAZACLO TABLET DISPERSIBLE 200 MG ORAL... 3 FAZACLO TABLET DISPERSIBLE 25 MG ORAL... 3 FYCOMPA SUSPENSION 0.5 MG/ML ORAL... 1 FYCOMPA TABLET 10 MG ORAL... 1 FYCOMPA TABLET 12 MG ORAL... 1 FYCOMPA TABLET 2 MG ORAL... 1 FYCOMPA TABLET 4 MG ORAL... 1 FYCOMPA TABLET 6 MG ORAL... 1 FYCOMPA TABLET 8 MG ORAL... 1 13

G GEODON SOLUTION RECONSTITUTED 20 MG INTRAMUSCULAR... 3 M MARPLAN TABLET 10 MG ORAL... 2 P PEGANONE TABLET 250 MG ORAL... 1 pimecrolimus cream 1 % external... 6 PROLIA SOLUTION 60 MG/ML SUBCUTANEOUS... 8 R RANEXA TABLET EXTENDED RELEASE 12 HOUR 1000 MG ORAL. 9 RANEXA TABLET EXTENDED RELEASE 12 HOUR 500 MG ORAL... 9 RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL... 10 RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL... 10 RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL... 10 RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL... 10 S SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL... 3 SAPHRIS TABLET SUBLINGUAL 2.5 MG SUBLINGUAL... 3 SAPHRIS TABLET SUBLINGUAL 5 MG SUBLINGUAL... 3 SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL... 1 SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL... 1 SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL... 1 SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL... 1 SYMPAZAN FILM 10 MG ORAL... 1 SYMPAZAN FILM 20 MG ORAL... 1 SYMPAZAN FILM 5 MG ORAL... 1 T TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/INH INHALATION... 11 U ULORIC TABLET 40 MG ORAL... 12 ULORIC TABLET 80 MG ORAL... 12 V VIIBRYD STARTER PACK KIT 10 & 20 MG ORAL... 2 VIIBRYD TABLET 10 MG ORAL... 2 VIIBRYD TABLET 20 MG ORAL... 2 VIIBRYD TABLET 40 MG ORAL... 2 VIMPAT SOLUTION 10 MG/ML ORAL. 1 VIMPAT TABLET 100 MG ORAL... 1 VIMPAT TABLET 150 MG ORAL... 1 VIMPAT TABLET 200 MG ORAL... 1 VIMPAT TABLET 50 MG ORAL... 1 VRAYLAR CAPSULE 1.5 MG ORAL... 3 VRAYLAR CAPSULE 3 MG ORAL... 3 VRAYLAR CAPSULE 4.5 MG ORAL... 3 VRAYLAR CAPSULE 6 MG ORAL... 3 VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL... 3 Z ZYPREXA RELPREVV SUSPENSION RECONSTITUTED 210 MG INTRAMUSCULAR... 3 14